Status:
COMPLETED
Anticoagulation Therapy After Splenectomy in Cirrhosis Patient
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Liver Cirrhosis
Portal Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
1\. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and p...
Detailed Description
1\. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and p...
Eligibility Criteria
Inclusion
- Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension
Exclusion
- Portal vein thrombosis found by preoperative color Doppler ultrasound or MRI examination;
- Liver cirrhosis complicated with liver tumor;
- Liver cirrhosis complicated with blood system diseases;
- Patients who have not signed the informed consent form.
Key Trial Info
Start Date :
February 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04397289
Start Date
February 12 2018
End Date
March 31 2021
Last Update
August 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the first hospital of xi'an jiaotong University
Xi'an, Shaanxi, China, 710061